Transversus abdominis plane block with liposomal bupivacaine for pain control after cesarean delivery: a retrospective chart review

B Wycke Baker1–4
Lea G Villadiego1,2
Y Natasha Lake1,2
Yazan Amin3
Audra E Timmins3
Laurie S Swaim3
David W Ashton3

1Department of Obstetrical and Gynecological Anesthesiology, Texas Children’s Hospital Pavilion for Women, Houston, TX, USA; 2US Anesthesia Partners, Houston, TX, USA; 3Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, USA; 4Department of Anesthesiology, Baylor College of Medicine, Houston, TX, USA

Background: Adverse effects of opioid analgesics and potential for chronic use are limitations in the cesarean setting. Regional anesthesia using transversus abdominis plane (TAP) block post-cesarean delivery may improve analgesia and reduce opioid consumption. Effectiveness of TAP block using liposomal bupivacaine (LB) to reduce post-cesarean pain is unknown.

Methods: We performed a single-center retrospective chart review of patients aged ≥18 years who underwent cesarean delivery with a multimodal pain management protocol with or without TAP block with LB 266 mg. Assessments included postsurgical opioid consumption; area under the curve (AUC) of numeric rating scale pain scores from 0 to 3 days; proportion of opioid-free patients; discharge- and post-anesthesia care unit (PACU)-ready time; times to ambulation, solid food, and bowel movement; hospital length of stay (LOS); and adverse events (AEs). Data were analyzed in the total population and in first- and repeat-cesarean subgroups using Wilcoxon, chi-squared, and Student’s t-tests.

Results: Of 201 patients, 101 were treated with LB TAP block (LB-TAPB) and 100 without LB-TAPB. Treatment with LB-TAPB vs without LB-TAPB significantly reduced mean postsurgical opioid consumption (total, 47%; first-cesarean, 54%; repeat-cesarean, 42%; \( P<0.001 \) each) and mean AUC of pain scores (total, 46%; first-cesarean, 57%; repeat-cesarean, 40%; \( P<0.001 \) each). Patients treated with LB-TAPB had significantly shorter mean discharge-ready times (2.9 vs 3.6 days; \( P=0.006 \)), PACU-ready times (138 vs 163 minutes; \( P=0.028 \)), and LOS (2.9 vs 3.9 days; \( P<0.001 \)). LB-TAPB significantly decreased mean times to ambulation and solid food by 39% and 31% (\( P<0.01 \) each), respectively, and numerically reduced mean time to bowel movement (26%; \( P=0.05 \)). Fewer patients treated with LB-TAPB vs without LB-TAPB reported an AE (34% vs 50%; \( P=0.026 \)).

Conclusion: These results suggest multimodal pain management incorporating TAP block with LB 266 mg is an effective approach to reducing opioid requirements and improving analgesia post-cesarean delivery.

Keywords: transversus abdominis plane block, liposomal bupivacaine, cesarean section, postoperative pain management

Introduction

Cesarean delivery was the most common US operating room procedure in 2014, accounting for 9% of such procedures1 and 32% of births.2 Many women experience moderate to severe post-cesarean pain.3 Inadequately managed postsurgical pain can interfere with maternal–infant bonding and is associated with delayed recovery, postpartum depression, persistent pain, and reduced success with breastfeeding.4
The benefits of opioid analgesics with regard to postsurgical pain must be weighed against the potential for adverse effects in the mother and infant.\(^5\) Opioid-related adverse events (ORAEs) such as nausea, vomiting, respiratory depression, and hypotension are distressing, can vary in severity, and in rare circumstances are life-threatening.\(^5\) In breastfed infants, maternal opioid use has the potential to cause central nervous system depression if the doses are high or use is prolonged.\(^6\) The current opioid epidemic in the US\(^7,8\) warrants vigilance toward opioid prescribing and any potential for opioid misuse and abuse after cesarean delivery. A retrospective health claims study including 201,662 patients who underwent cesarean delivery determined that these women have a 28% increased risk for chronic opioid use compared with those not undergoing a surgery.\(^9\) A recent retrospective, single-center study of postpartum opioid prescribing suggested that many women leaving the hospital with an opioid prescription reported no pain at discharge or used no opioids in the last 24 hours of hospitalization.\(^10\) Although women often do not consume all the prescribed medication, leftover opioids are potentially hazardous because they pose a risk for diversion.\(^11,12\) Recognizing the possible risks of long-term opioid use, benefits of reduced postsurgical opioid consumption, and that opioids are not always required for postsurgical pain, professional practice society guidelines\(^13\) have recommended implementation of multimodal postsurgical pain management strategies to reduce opioid use.

Multimodal approaches to control post-cesarean pain can include systemic opioids, nonsteroidal anti-inflammatory drugs, or acetaminophen; infiltration of local anesthetic at the incision site; epidural or intrathecal opioids; and transversus abdominis plane (TAP) block.\(^13\) Two meta-analyses of randomized controlled trials (RCTs) showed reductions in post-cesarean pain scores and opioid usage using TAP block compared with placebo when spinal morphine was omitted,\(^14,15\) whereas a third meta-analysis showed less consistent findings.\(^16\) In these same studies, in the presence of spinal opioids, the nist combination, every 2 hours as needed for breakthrough received IV nalbuphine 2 mg, a mixed opioid agonist–antagonist with three doses of IV ketorolac 30 mg every 6 hours for 24 hours. For patient-reported NRS scores of 6 to 10, patients received three doses of IV acetaminophen 10 mg/mL (15 mg/kg if body weight \(\geq\) 50 kg; 1,000 mg if body weight \(\geq\) 50 kg) every 6 hours, alternated with three doses of IV ketorolac 30 mg every 6 hours for 24 hours. For patient-reported NRS scores of 6 to 10, patients received IV nalbuphine 2 mg, a mixed opioid agonist–antagonist combination, every 2 hours as needed for breakthrough pain for 24 hours. In late 2014, ultrasound-guided LB-TAPB was added to the protocol. Patients received bilateral single-shot injections of 10 mL LB (133 mg) admixed with 15 mL 0.25% bupivacaine HCl expanded with 15 mL normal saline (total 40 mL injection per side).

**Methods**

**Study design and patients**

This was a single-center retrospective review of charts from 201 consecutive women 18–65 years of age who underwent elective, unscheduled waiting list, or emergency cesarean delivery with anesthesia and post-cesarean pain management by one anesthesiologist (BWB) at Texas Children’s Hospital Pavilion for Women between 2012 and 2015. The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice and the Declaration of Helsinki and approved by an Institutional Review Board (IRB). Because data collection included deidentified patient records, the IRB granted a waiver of written informed consent.

**Postsurgical pain management protocol**

From 2012 to late 2014, the institution utilized a multimodal post-cesarean pain management protocol that comprised combined spinal-epidural anesthesia with intrathecal morphine (100 µg) and supplemental intravenous (IV) analgesics. Dosing of IV analgesics was based on patient-reported pain intensity assessed using a numeric rating scale (NRS; range, 0 [no pain] to 10 [worst possible pain]). For patient-reported NRS scores of 1 to 5, patients received three doses of IV acetaminophen 10 mg/mL (15 mg/kg if body weight <50 kg; 1,000 mg if body weight \(\geq\) 50 kg) every 6 hours, alternated with three doses of IV ketorolac 30 mg every 6 hours for 24 hours. For patient-reported NRS scores of 6 to 10, patients received IV nalbuphine 2 mg, a mixed opioid agonist–antagonist combination, every 2 hours as needed for breakthrough pain for 24 hours. In late 2014, ultrasound-guided LB-TAPB was added to the protocol. Patients received bilateral single-shot injections of 10 mL LB (133 mg) admixed with 15 mL 0.25% bupivacaine HCl expanded with 15 mL normal saline (total 40 mL injection per side).

**Assessments**

Data were collected and entered into a secure Health Insurance Portability and Accountability Act of 1996 (HIPAA)-compliant, cloud-based OpenClinica (Waltham, MA) data

---

**Notes:**

1. In light of this knowledge gap, we designed this retrospective chart review to evaluate the effectiveness and safety of a multimodal pain management protocol with or without LB TAP block (LB-TAPB) for cesarean delivery.

2. Liposomal bupivacaine (LB, EXPAREL®; Pacira Pharmaceuticals, Inc., Parsippany, NJ, USA) is a prolonged-release formulation of bupivacaine that is approved by the US Food and Drug Administration (FDA) for single-dose infiltration of bupivacaine that is approved by the US Food and Drug Administration (FDA) for single-dose infiltration for postsurgical analgesia,\(^17\) including TAP block. LB has been shown to reduce postsurgical pain and opioid consumption for up to 72 hours when administered via local wound infiltration.\(^18\) In cesarean delivery, intracurricular infiltration of LB after completion of surgery has been shown to reduce opioid consumption compared with usual care.\(^19\) Although
Multimodal pain management with LB-TAPB significantly reduced mean postsurgical opioid consumption by 47% in the total population and by 54% and 42% in the first- and repeat-cesarean subgroups, respectively (Table 2). When analyzed by postsurgical day, reductions in opioid consumption with vs without LB-TAPB were significant for day 3 (total population, 47%; first, 60%; repeat, 38%), with nonsignificant numeric reductions on postsurgical day 2 (total population, 43%; first, 63%; repeat, 33%). In the total population, a significantly greater percentage of patients treated with LB-TAPB (12%) vs without LB-TAPB (3%) consumed no opioids after surgery (P=0.017). There was no significant difference in the proportion of opioid-free patients in the first-cesarean subgroup (6% vs 5%, P=0.916). In the repeat-cesarean subgroup, 15% of patients treated with LB-TAPB vs no patients treated without LB-TAPB were opioid-free.

Multimodal pain management with LB-TAPB significantly reduced mean AUC of pain scores by 46% in the total population and by 57% and 40% in the first- and repeat-cesarean subgroups, respectively (Table 2). When analyzed by postsurgical day, improvements in pain scores in the total population were significant for day 3 (44%), with a nonsignificant numeric reduction on day 2 (41%). Reductions in pain scores were also significant for day 3 in the first- (52%) and repeat-cesarean subgroups (40%).

In the total population, patients treated with LB-TAPB vs without LB-TAPB had significantly reduced mean (95% CI) discharge-ready time (Figure 1A) and PACU-ready time (138 [122.8–153.2] vs 163 [103.2–222.8] minutes, respectively; P=0.028). Discharge-ready time was significantly decreased with LB-TAPB vs without LB-TAPB in the first-cesarean subgroup and numerically decreased in the repeat-cesarean subgroup (Figure 1B).

### Table 1 Patient demographics and baseline clinical characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total</th>
<th>With LB-TAPB (n=101)</th>
<th>Without LB-TAPB (n=100)</th>
<th>P-value*</th>
<th>First-cesarean</th>
<th>With LB-TAPB (n=34)</th>
<th>Without LB-TAPB (n=56)</th>
<th>P-value*</th>
<th>Repeat-cesarean</th>
<th>With LB-TAPB (n=67)</th>
<th>Without LB-TAPB (n=44)</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD) age, years</td>
<td>33 (6)</td>
<td>35 (6)</td>
<td>32.4 (6.8)</td>
<td>0.089</td>
<td>33 (6)</td>
<td>30.4 (5.5)</td>
<td>33.0 (7.5)</td>
<td>0.091</td>
<td>34 (6)</td>
<td>34 (6)</td>
<td>33.4 (7.2)</td>
<td>0.094</td>
</tr>
<tr>
<td>Mean (SD) BMI, kg/m²</td>
<td>23 (2.0)</td>
<td>23 (2.0)</td>
<td>22 (2.0)</td>
<td>0.224</td>
<td>23 (2.0)</td>
<td>22 (2.0)</td>
<td>22 (2.0)</td>
<td>0.454</td>
<td>20 (2.0)</td>
<td>20 (2.0)</td>
<td>20 (2.0)</td>
<td>0.166</td>
</tr>
<tr>
<td>ASA status, n (%)</td>
<td>77 (77.0)</td>
<td>83 (83.8)</td>
<td>16 (16.2)</td>
<td>0.705</td>
<td>83 (83.8)</td>
<td>83 (83.8)</td>
<td>16 (16.2)</td>
<td>0.054</td>
<td>83 (83.8)</td>
<td>83 (83.8)</td>
<td>16 (16.2)</td>
<td>0.054</td>
</tr>
</tbody>
</table>
| Notes: *P-values were calculated using a two-tailed Student’s t-test or Wilcoxon signed-rank test (continuous variables) or a Pearson’s chi-squared test (categorical variables). Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; LB-TAPB, transversus abdominis plane block with liposomal bupivacaine.
In the total population, patients treated with LB-TAPB vs without LB-TAPB had significantly reduced mean hospital LOS (Figure 2A). In the first-cesarean subgroup, there was also a significant reduction in LOS in the group receiving LB-TAPB (Figure 2B), whereas in the repeat-cesarean subgroup, there was a nonsignificant numeric reduction (Figure 2B). All patients were discharged to home.

Multimodal pain management with LB-TAPB significantly decreased mean time to ambulation and solid food in the total population, and there was a nonsignificant numeric reduction in mean time to bowel movement (Table 3). In the first-cesarean group, LB-TAPB significantly decreased all functional outcomes, whereas nonsignificant numeric reductions were seen in the repeat-cesarean subgroup (Table 3). 

**Safety**

In the total population, significantly fewer patients receiving multimodal pain management with LB-TAPB vs without LB-TAPB reported an AE (Table 4). The most commonly reported ORAEs were nausea, pruritus, and vomiting (Table 4). In the first-cesarean group, numerically fewer patients reported an AE with LB-TAPB vs without LB-TAPB.

### Table 2 Mean total postsurgical opioid consumption and AUC of NRS pain scores

<table>
<thead>
<tr>
<th>Arithmetic mean (SD)</th>
<th>Total</th>
<th>Without LB-TAPB (n=101)</th>
<th>With LB-TAPB (n=100)</th>
<th>P-value*</th>
<th>First-cesarean</th>
<th>Without LB-TAPB (n=56)</th>
<th>With LB-TAPB (n=57)</th>
<th>P-value*</th>
<th>Repeat-cesarean</th>
<th>Without LB-TAPB (n=44)</th>
<th>With LB-TAPB (n=67)</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total postsurgical opioid consumption (MED), mg</td>
<td>n=89</td>
<td>n=97</td>
<td>41.9 (37.4)</td>
<td>79.6 (60.2)</td>
<td>&lt;0.001</td>
<td>n=32</td>
<td>38.1 (34.2)</td>
<td>82.1 (61.9)</td>
<td>&lt;0.001</td>
<td>n=57</td>
<td>44.0 (39.1)</td>
<td>76.5 (58.7)</td>
</tr>
<tr>
<td>Postsurgical day 1</td>
<td>n=17</td>
<td>n=8</td>
<td>25.1</td>
<td>60</td>
<td>ND</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>ND</td>
<td>n=1</td>
<td>25</td>
<td>60</td>
</tr>
<tr>
<td>Postsurgical day 2</td>
<td>n=49</td>
<td>n=42</td>
<td>29.2 (25.4)</td>
<td>51.3 (51.8)</td>
<td>0.482</td>
<td>n=20</td>
<td>26.7 (15.3)</td>
<td>72.5 (95.5)</td>
<td>1.000</td>
<td>n=29</td>
<td>29.7 (27.5)</td>
<td>44.2 (41.2)</td>
</tr>
<tr>
<td>Postsurgical day 3</td>
<td>n=54</td>
<td>n=49</td>
<td>44.9 (42.0)</td>
<td>84.4 (64.1)</td>
<td>&lt;0.001</td>
<td>n=19</td>
<td>33.1 (34.8)</td>
<td>83.7 (75.4)</td>
<td>0.002</td>
<td>n=35</td>
<td>52.9 (45.1)</td>
<td>84.8 (56.8)</td>
</tr>
<tr>
<td>Total AUC of NRS pain scores from 0 to 3 daysa</td>
<td>n=132</td>
<td>n=124</td>
<td>132.8 (98.3)</td>
<td>246.3 (102.8)</td>
<td>&lt;0.001</td>
<td>n=190</td>
<td>109.0 (82.7)</td>
<td>250.7 (109.4)</td>
<td>&lt;0.001</td>
<td>n=145</td>
<td>147.5 (104.7)</td>
<td>244.0 (100.8)</td>
</tr>
<tr>
<td>Postsurgical day 1</td>
<td>n=1</td>
<td>n=1</td>
<td>71.7</td>
<td>257.3</td>
<td>ND</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>ND</td>
<td>n=1</td>
<td>71.7</td>
<td>257.3</td>
</tr>
<tr>
<td>Postsurgical day 2</td>
<td>n=12</td>
<td>n=7</td>
<td>97.2 (77.3)</td>
<td>163.4 (109.1)</td>
<td>0.030</td>
<td>n=3</td>
<td>53.8 (37.3)</td>
<td>252.9 (112.9)</td>
<td>0.437</td>
<td>n=9</td>
<td>111.7 (83.3)</td>
<td>148.5 (111.4)</td>
</tr>
<tr>
<td>Postsurgical day 3</td>
<td>n=41</td>
<td>n=41</td>
<td>144.7 (102.7)</td>
<td>260.2 (97.4)</td>
<td>&lt;0.001</td>
<td>n=16</td>
<td>119.4 (85.4)</td>
<td>250.6 (112.9)</td>
<td>0.005</td>
<td>n=25</td>
<td>160.9 (111.0)</td>
<td>266.4 (87.9)</td>
</tr>
</tbody>
</table>

**Notes:** P-values were calculated using a two-tailed Student’s t-test or Wilcoxon signed-rank test. Analysis included only those patients with a length of stay of 3 days. Abbreviations: AUC, area under the curve; LB-TAPB, transversus abdominis plane block with liposomal bupivacaine; MED, morphine equivalent dose; NA, not available; ND, not determined; NRS, numeric rating scale.

![Figure 1](https://journal.dovepress.com/654-70.11/sit www.dovepress.com). Mean discharge-ready time in the (A) total patient population and (B) first- and repeat-cesarean patients. P-value was calculated using Student’s t-test. Abbreviation: LB-TAPB, transversus abdominis plane block with liposomal bupivacaine.
and in the repeat-cesarean group significantly fewer patients reported an AE with LB-TAPB vs without LB-TAPB.

**Discussion**

In this retrospective study, administering TAP block with LB 266 mg as part of a multimodal post-cesarean pain management protocol significantly reduced pain intensity and total inpatient postsurgical opioid consumption. In addition, this pain management approach significantly improved discharge- and PACU-ready times, functional recovery, and LOS. Further, patients receiving multimodal pain management with LB-TAPB reported significantly fewer AEs overall. These results suggest that multimodal pain management incorporating LB-TAPB is an effective approach to improving outcomes in women undergoing cesarean delivery.

Our results add to the growing literature on regional analgesia approaches such as TAP block and quadratus lumborum block for cesarean section. Results of a meta-analysis

---

**Table 3** Mean times to ambulation, solid food, and bowel movement

<table>
<thead>
<tr>
<th>Mean (SD), hours</th>
<th>Total</th>
<th>First-cesarean</th>
<th>Repeat-cesarean</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to ambulation</td>
<td>With LB-TAPB (n=67)</td>
<td>Without LB-TAPB (n=60)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Time to solid food</td>
<td>With LB-TAPB (n=19)</td>
<td>Without LB-TAPB (n=29)</td>
<td>17.7 (8.5)</td>
</tr>
<tr>
<td>Time to bowel movement</td>
<td>With LB-TAPB (n=48)</td>
<td>Without LB-TAPB (n=31)</td>
<td>24.1 (14.2)</td>
</tr>
</tbody>
</table>

Note: *P*-value was calculated using Student’s t-test.

Abbreviation: LB-TaPB, transversus abdominis plane block with liposomal bupivacaine.

**Table 4** Adverse events

<table>
<thead>
<tr>
<th>n (%)</th>
<th>Total</th>
<th>First-cesarean</th>
<th>Repeat-cesarean</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with ≥1 AE</td>
<td>With LB-TAPB (n=101)</td>
<td>Without LB-TAPB (n=100)</td>
<td>0.026</td>
</tr>
<tr>
<td>ORAEs of interest</td>
<td>n=101</td>
<td>n=67</td>
<td>0.026</td>
</tr>
<tr>
<td>Nausea</td>
<td>n=101</td>
<td>n=67</td>
<td>23 (45.1)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>n=101</td>
<td>n=67</td>
<td>17 (48.6)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>n=101</td>
<td>n=67</td>
<td>6 (46.2)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>n=101</td>
<td>n=67</td>
<td>6 (46.2)</td>
</tr>
</tbody>
</table>

Note: *P*-value was calculated using chi-squared test.

Abbreviations: AE, adverse event; LB-TaPB, transversus abdominis plane block with liposomal bupivacaine; ORAEs, opioid-related adverse events.
of RCTs evaluating the effectiveness of TAP block with bupivacaine, ropivacaine, or levobupivacaine after cesarean delivery show superiority over placebo or no block with respect to analgesia and opioid consumption, although showing little benefit when added to or compared with intrathecal morphine alone. A systematic review of eleven RCTs demonstrated high levels of patient satisfaction, increased time to first analgesia request, and reduced postoperative nausea and vomiting with the addition of TAP block vs placebo to spinal anesthesia for cesarean delivery.

Reduced opioid consumption was observed in an earlier retrospective case-control study using LB infiltrated at the cesarean incision site, an approach that has shown comparable effectiveness to TAP block in this surgical setting. Although a recent pilot RCT evaluating wound infiltration with LB for post-cesarean pain showed no treatment effect with respect to pain on movement at 48 hours, the primary outcome, results may have been affected by an apparent floor effect, as pain scores in the placebo group were lower than those used to power the study. In our study, multimodal pain management incorporating LB-TAPB produced prolonged analgesia, as demonstrated by a 46% improvement in AUC pain scores and a 44% improvement in pain scores on postsurgical day 3. Consistent with these analgesic benefits, multimodal pain management incorporating LB-TAPB significantly reduced opioid consumption by 47% overall and on day 3. Although there were similar trends for pain scores and opioid use on postsurgical day 2, the between-group differences did not reach significance, likely due to the small sample size for this time point.

These findings are important in light of the opioid epidemic in the US and the shift toward multimodal pain management approaches that can provide effective opioid-sparing post-cesarean analgesia. Prescription of postsurgical opioids is nearly universal among surgical patients, including women undergoing cesarean delivery. Up to 14% of patients prescribed an opioid for postsurgical pain experienced an ORAE, which is associated with increased hospital LOS, greater risk of readmission, greater inpatient mortality, and higher total costs. Cesarean delivery is associated with a 28% increase in the incidence of persistent postsurgical opioid use, and leftover opioid medication has the potential for diversion. The Centers for Disease Control and American College of Surgeons have both recommended that physicians limit the use of opioids postoperatively. Our findings suggest that the addition of LB-TAPB to a multimodal pain management protocol may be an effective opioid-sparing strategy for cesarean delivery.

The advantages of TAP block for cesarean delivery should be weighed against risks, including the rare but potentially serious occurrence of local anesthetic systemic toxicity (LAST) subsequent to inadvertent intravenous administration. TAP block requires the injection of relatively high volumes and drug doses into a vascular space, which, along with pregnancy, may increase LAST risk. Preventive measures include the use of ultrasound guidance, consistent with technique in the current study. LB was not injected unless the TAP plane was clearly visualized, aspiration for the return of blood was performed before and after each 5 mL injection, and patients were monitored closely for signs and symptoms of LAST. Circulating plasma concentrations of local anesthetics are especially pertinent to the occurrence of LAST. Compared to immediate-release bupivacaine HCl, LB displays a slower release of bupivacaine and a lower initial maximum plasma concentration followed by extended release over time. A recent analysis of the FDA AE reporting database suggests that the incidence of possible LAST cases with LB is similar to or less than that with other injectable local anesthetics.

Cesarean delivery is associated with ~50% greater costs compared with vaginal delivery for both Medicaid and commercial health insurance payers. LOS and ORAEs are important drivers of costs of care in surgical patients. Although the current study did not directly assess costs associated with LB-TAPB, the observed improvements in functional recovery, discharge-ready time, and LOS suggest a potential for overall cost savings. However, this requires substantiation in future prospective studies evaluating hospital-related costs associated with LB-TAPB vs TAP block with other local anesthetics.

Limitations of this study include its retrospective nature, which required accurate record keeping to maintain data validity. Baseline demographic and clinical characteristics were limited, and results may have been affected by uncontrolled confounding factors such as imbalance in the number of first- and repeat-cesarean patients in the two treatment groups. The use of a single site and anesthesiologist may limit the generalizability of the findings, in addition to being a potential source of bias; however, this may also be considered a strength because it ensured consistency with regard to protocols and infiltration techniques. The subgroup analyses in patients undergoing a first- or repeat-cesarean delivery were exploratory, likely underpowered due to small sample size, and potentially affected by uncontrolled confounding factors. Prospective RCTs evaluating the effectiveness of LB-TAPB vs TAP block with other local anesthetics are needed.
to further define the utility of this approach for cesarean delivery. Evaluation of effects on lactation, breastfeeding, and bupivacaine levels in breast milk would further inform the effects of this approach on functional recovery.

Conclusion
These results suggest that multimodal pain management incorporating TAP block with LB 266 mg is an effective approach to reducing opioid reliance and improving analgesia after cesarean delivery with no unexpected safety signals. These results are important in light of the need for opioid-sparing pain management strategies and provide the basis for a future prospective RCT to assess the efficacy of a standardized multimodal postsurgical pain management protocol incorporating LB-TAPB for post-cesarean analgesia.

Ethics approval and informed consent
This study (H-40158) was approved by the Institutional Review Board for Human Subject Research for Baylor College of Medicine and Affiliated Hospitals. Because data collection included deidentified patient records, the IRB granted a waiver of written informed consent.

Data availability
Data requests will be considered on an individual basis. Requests should go to the corresponding author.

Acknowledgments
The authors would like to acknowledge Amiee Kang, MPH, a former employee of Pacira Pharmaceuticals, Inc., for assistance with statistical analyses. Editorial support for development of this manuscript was provided by Krystina Neuman, PhD, at C4 MedSolutions, LLC (Yardley, PA), a CHC Group company, and was funded by Pacira Pharmaceuticals, Inc. Pacira Pharmaceuticals, Inc. was involved in the analysis and interpretation of the data and review of the manuscript. This paper was presented at the SOAP 50th Annual Meeting held in Miami, FL, USA, May 9–13, 2018, as a poster and published online at https://epostersonline.com/soap2018/node/194.

Author contributions
All authors participated in the study conception or design or acquisition, analysis, or interpretation of the work and contributed to drafting or revising the article; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Disclosure
BW Baker received research funding and consulting fees from Pacira Pharmaceuticals, Inc. LG Villadiego received research funding from Pacira Pharmaceuticals, Inc. The authors report no other conflicts of interest in this work.

References


